Our work demonstrate that propofol has potential to be repurposed for CML treatment given its combinatory efficacy with BCR-ABL TKI in in vitro and in vivo without affecting NBM cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.